Biologics Manufacturing Market Size, Share & Trends Report

Biologics Manufacturing Market (2025 - 2033) Size, Share & Trends Analysis Report By Mode Of Manufacturing (Contract, In-House), By Modality, By Disease Indication, By Region, And Segment Forecasts

Market Segmentation

Biologics Manufacturing Mode Outlook (Revenue, USD Million, 2021 - 2033)
- Contract Manufacturing
- In-house manufacturing
Biologics Manufacturing Modality Outlook (Revenue, USD Million, 2021 - 2033)
- Monoclonal Antibodies (mAbs)
- Biosimilar & Recombinant Proteins
- Vaccines (recombinant/mRNA/Viral)
- Cell & Gene Therapies
- RNA-based Therapeutics
- Others
Biologics Manufacturing Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Oncology
- Autoimmune Disorders
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Disorders
- Other Disease Indications
Biologics Manufacturing Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
  - North America biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
    - Contract Manufacturing
    - In-house manufacturing
  - North America biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
    - Monoclonal Antibodies (mAbs)
    - Biosimilar & Recombinant Proteins
    - Vaccines (recombinant/mRNA/Viral)
    - Cell & Gene Therapies
    - RNA-based Therapeutics
    - Others
  - North America biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
    - Oncology
    - Autoimmune Disorders
    - Infectious Diseases
    - Neurological Disorders
    - Cardiovascular Disorders
    - Other Disease Indications
  - U.S.
    - U.S. biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - U.S. biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - U.S. biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Canada
    - Canada biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Canada biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Canada biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
- Europe
  - Europe biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
    - Contract Manufacturing
    - In-house manufacturing
  - Europe biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
    - Monoclonal Antibodies (mAbs)
    - Biosimilar & Recombinant Proteins
    - Vaccines (recombinant/mRNA/Viral)
    - Cell & Gene Therapies
    - RNA-based Therapeutics
    - Others
  - Europe biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
    - Oncology
    - Autoimmune Disorders
    - Infectious Diseases
    - Neurological Disorders
    - Cardiovascular Disorders
    - Other Disease Indications
  - Germany
    - Germany biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Germany biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Germany biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - UK
    - UK biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - UK biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - UK biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - France
    - France. biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - France biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - France biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Italy
    - Italy biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Italy biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Italy biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Spain
    - Spain biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Spain biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Spain biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Denmark
    - Denmark biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Denmark biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Denmark biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Sweden
    - Sweden biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Sweden biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Sweden biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Norway
    - Norway biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Norway biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Norway biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
- Asia Pacific
  - Asia Pacific biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
    - Contract Manufacturing
    - In-house manufacturing
  - Asia Pacific biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
    - Monoclonal Antibodies (mAbs)
    - Biosimilar & Recombinant Proteins
    - Vaccines (recombinant/mRNA/Viral)
    - Cell & Gene Therapies
    - RNA-based Therapeutics
    - Others
  - Asia Pacific biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
    - Oncology
    - Autoimmune Disorders
    - Infectious Diseases
    - Neurological Disorders
    - Cardiovascular Disorders
    - Other Disease Indications
  - China
    - China biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - China biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - China biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - India
    - India biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - India biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - India biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Japan
    - Japan biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Japan biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Japan biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - South Korea
    - South Korea biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - South Korea biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - South Korea biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Australia
    - Australia biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Australia biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Australia biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Thailand
    - Thailand biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Thailand biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Thailand biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
- Latin America
  - Latin America biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
    - Contract Manufacturing
    - In-house manufacturing
  - Latin America biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
    - Monoclonal Antibodies (mAbs)
    - Biosimilar & Recombinant Proteins
    - Vaccines (recombinant/mRNA/Viral)
    - Cell & Gene Therapies
    - RNA-based Therapeutics
    - Others
  - Latin America biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
    - Oncology
    - Autoimmune Disorders
    - Infectious Diseases
    - Neurological Disorders
    - Cardiovascular Disorders
    - Other Disease Indications
  - Brazil
    - Brazil biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Brazil biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Brazil biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Mexico
    - Mexico biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Mexico biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Mexico biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Argentina
    - Argentina biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Argentina biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Argentina biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
- Middle East and Africa (MEA)
  - Middle East and Africa (MEA) biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
    - Contract Manufacturing
    - In-house manufacturing
  - Middle East and Africa (MEA) biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
    - Monoclonal Antibodies (mAbs)
    - Biosimilar & Recombinant Proteins
    - Vaccines (recombinant/mRNA/Viral)
    - Cell & Gene Therapies
    - RNA-based Therapeutics
    - Others
  - Middle East and Africa (MEA) biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
    - Oncology
    - Autoimmune Disorders
    - Infectious Diseases
    - Neurological Disorders
    - Cardiovascular Disorders
    - Other Disease Indications
  - South Africa
    - South Africa biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - South Africa biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - South Africa biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Saudi Arabia
    - Saudi Arabia biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Saudi Arabia biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Saudi Arabia biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - UAE
    - UAE biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - UAE biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - UAE biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications
  - Kuwait
    - Kuwait biologics manufacturing market, By Mode, 2021 - 2033 (USD Million)
      - Contract Manufacturing
      - In-house manufacturing
    - Kuwait biologics manufacturing market, By Modality, 2021 - 2033 (USD Million)
      - Monoclonal Antibodies (mAbs)
      - Biosimilar & Recombinant Proteins
      - Vaccines (recombinant/mRNA/Viral)
      - Cell & Gene Therapies
      - RNA-based Therapeutics
      - Others
    - Kuwait biologics manufacturing market, By Disease Indication, 2021 - 2033 (USD Million)
      - Oncology
      - Autoimmune Disorders
      - Infectious Diseases
      - Neurological Disorders
      - Cardiovascular Disorders
      - Other Disease Indications

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments